ES2119165T3 - Nueva actividad de cofactor anticoagulante. - Google Patents

Nueva actividad de cofactor anticoagulante.

Info

Publication number
ES2119165T3
ES2119165T3 ES94905908T ES94905908T ES2119165T3 ES 2119165 T3 ES2119165 T3 ES 2119165T3 ES 94905908 T ES94905908 T ES 94905908T ES 94905908 T ES94905908 T ES 94905908T ES 2119165 T3 ES2119165 T3 ES 2119165T3
Authority
ES
Spain
Prior art keywords
cofactor
activity
apc
protein
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94905908T
Other languages
English (en)
Other versions
ES2119165T5 (es
Inventor
Bjorn Dahlback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2119165(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9300300A external-priority patent/SE9300300D0/xx
Priority claimed from SE9302457A external-priority patent/SE9302457D0/xx
Application filed by Individual filed Critical Individual
Publication of ES2119165T3 publication Critical patent/ES2119165T3/es
Application granted granted Critical
Publication of ES2119165T5 publication Critical patent/ES2119165T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96463—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

UNA ACTIVIDAD ANTICOAGULANTE SANGUINEA NOVEDOSA, LLAMADA ACTIVIDAD 2 DE COFACTOR-APC, ES DECIR LA SEGUNDA ACTIVIDAD DE COFACTOR A LA PROTEINA C ( = APC) ACTIVADA. LA ACTIVIDAD DE COFACTOR ES PROBABLE QUE SEA ASOCIADA CON EL FACTOR V, POR QUE SE COMPORTA COMO UNA PROTEINA QUE PUEDE SER ENRIQUECIDA DESDE EL PLASMA CON METODOS QUE SON SIMILARES A AQUELLOS PARA EL FACTOR V. EN EL PAGE-SDS, LA FRACCION ENRIQUECIDA DA ORIGEN A TRES BANDAS MOLECULARES EN 175-250 KD. Y 100-180 KD. Y 330 KD. RESPECTICAMENTE. SE DESCRIBEN LOS DIFERENTES ASPECTOS, TALES COMO LAS PREPARACIONES ENRIQUECIDAS O DEFICIENTES EN LA ACTIVIDAD DE COFACTOR; LAS PREPARACIONES DE ANTICUERPOS ESPECIFICAS PARA LAS LOCALIZACIONES DE FACTOR V, ASOCIADAS CON LA ACTIVIDAD 2 DE COFACTOR APC; LOS USOS DE DIAGNOSTICO Y TERAPEUTICOS EN CONEXION CON EL TRATAMIENTO DE DESORDENES RELACIONADOS A DEFICIENCIAS EN LA ACTIVIDAD 2 DE COFACTOR APC, PROTEINA C Y/O PROTEINA S ADEMAS DE LOS DISTINTOS USOS DE PREPARACIONES ENRIQUECIDAS EN LA ACTIVIDAD 2DE COFACTOR APC (FACTOR V NORMAL), PROTEINA C/APC Y /O PROTEINA S. LA ACTIVIDAD 2 DE COFACTOR APC TAMBIEN PUEDE SER UTILIZADA TERAPEUTICAMENTE EN CONEXION CON OTRAS ENFERMEDADES, EN LAS CUALES LA ADMINISTRACION DEL COFACTOR ES BENEFICIOSA PARA EL PACIENTE.
ES94905908T 1993-01-29 1994-01-28 Nueva actividad de cofactor anticoagulante. Expired - Lifetime ES2119165T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9300300A SE9300300D0 (sv) 1993-01-29 1993-01-29 A novel anticoagulant entity, antibodies reacting specifically with the entity, and diagnostic and therapeutic used of the entity
SE9300300 1993-01-29
SE9302457A SE9302457D0 (sv) 1993-07-20 1993-07-20 A novel anticoagulant entity, antibodies reacting specifically with the enety, and diagnostic and therapeutic uses of the entity
SE9302457 1993-07-20

Publications (2)

Publication Number Publication Date
ES2119165T3 true ES2119165T3 (es) 1998-10-01
ES2119165T5 ES2119165T5 (es) 2004-07-01

Family

ID=26661641

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94905908T Expired - Lifetime ES2119165T5 (es) 1993-01-29 1994-01-28 Nueva actividad de cofactor anticoagulante.

Country Status (17)

Country Link
US (2) US7169572B1 (es)
EP (1) EP0690991B2 (es)
JP (1) JPH08506181A (es)
AT (1) ATE168781T1 (es)
AU (1) AU690535B2 (es)
BR (1) BR9406223A (es)
CA (1) CA2154080C (es)
CZ (1) CZ184995A3 (es)
DE (1) DE69411898T3 (es)
DK (1) DK0690991T4 (es)
ES (1) ES2119165T5 (es)
FI (1) FI953565A0 (es)
GR (1) GR3027697T3 (es)
HU (1) HUT72191A (es)
NZ (1) NZ261190A (es)
PL (1) PL181102B1 (es)
WO (1) WO1994017415A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017415A1 (en) * 1993-01-29 1994-08-04 Dahlbaeck Bjoern Novel anticoagulant cofactor activity
AU690644B2 (en) * 1994-02-14 1998-04-30 Rijksuniversiteit Leiden A method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein C
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
DE4439756C2 (de) * 1994-11-09 2002-07-18 Dade Behring Marburg Gmbh Kalibrator zur Verwendung in Testverfahren zum Nachweis eines defekten Gerinnungsfaktors V
ES2154703T5 (es) * 1994-11-10 2008-02-01 Dade Behring Marburg Gmbh Procedimiento para la deteccion especifica de un factor de coagulacion v activado con una estabilidad elevada frente a proteina c activada.
US6867045B1 (en) * 1994-11-14 2005-03-15 The Scripps Research Institute Method for diagnosis of thrombotic disorders
ATE200710T1 (de) * 1994-12-23 2001-05-15 Diagnostic Reagents Ltd Verfahren zur diagnose von blutgerinnungsstörungen
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
US5863896A (en) * 1995-11-09 1999-01-26 Immuno Ag Evaluation of substances for altering and for increasing APC response
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
DE19634312A1 (de) * 1996-08-24 1998-02-26 Behringwerke Ag Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma
WO1999058699A2 (en) * 1998-05-14 1999-11-18 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors
FR2778923B1 (fr) * 1998-05-22 2000-08-18 Stago Diagnostica Compositions utiles comme controle pathologique dans une methode de detection d'une resistance a la proteine c activee, procede de preparation de ces compositions et utilisation dans ladite methode de detection
JP4377207B2 (ja) 2003-11-28 2009-12-02 シスメックス株式会社 血液凝固時間測定方法および血液凝固時間測定用試薬
US20100322921A1 (en) * 2006-10-16 2010-12-23 Rekha Bansal METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF
CN110192105B (zh) * 2017-01-06 2022-04-12 索尼公司 凝血系统分析和失血量预测装置、系统、方法和程序

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3330699A1 (de) 1983-08-25 1985-03-07 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
JPS60241900A (ja) 1984-05-16 1985-11-30 Nitto Boseki Co Ltd 新規な第Ｘａ因子活性測定用基質
DE3516579A1 (de) 1984-11-19 1986-05-22 Boehringer Mannheim Gmbh, 6800 Mannheim Gerinnungstest auf teststreifen
US4849403A (en) 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
DE3536903A1 (de) 1985-10-16 1987-04-16 Boehringer Mannheim Gmbh Verfahren zur photometrischen bestimmung von protein c
DE3607559A1 (de) 1986-03-07 1987-09-10 Boehringer Mannheim Gmbh Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet
US5200322A (en) * 1986-09-19 1993-04-06 Nippon Zoki Pharmaceutical Co., Ltd. Method for assaying protein C and measuring kit for the same
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5472850A (en) 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US5055412A (en) 1989-03-21 1991-10-08 Proksch Gary J Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same
IT1230744B (it) * 1989-07-07 1991-10-29 Instrumentation Lab Spa Metodo per la determinazione della attivita' funzionale della proteina s nel plasma umano.
SE464135B (sv) 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5051357A (en) * 1989-07-14 1991-09-24 Board Of Trustees Operating Michigan State University Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
WO1991001383A1 (en) 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
US5169786A (en) 1989-12-19 1992-12-08 Ortho Diagnostic Systems, Inc. Method of determining levels of extrinsic and intrinsic clotting factors and protein c
US5314695A (en) 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
AT395597B (de) 1991-01-25 1993-01-25 Immuno Ag Reagens zur bestimmung von faktor viii-aktivitaet
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
SE470274B (sv) 1991-11-13 1993-12-20 Bjoern Dahlbaeck Användning av en in vitro-metod för diagnos av blodkoagulationssjukdomar
JP2562000B2 (ja) 1991-11-13 1996-12-11 ダールベツク，ビヨルン 血液凝固疾患の診断方法
US5308756A (en) * 1991-11-20 1994-05-03 Baxter Diagnostics Inc. Protein S chromogenic assay
WO1994017415A1 (en) * 1993-01-29 1994-08-04 Dahlbaeck Bjoern Novel anticoagulant cofactor activity
DE59410041D1 (de) * 1993-12-03 2002-03-21 Baxter Ag Test zur Bestimmung der Empfindlichkeit gegenüber aktiviertem Protein C
DE4427785A1 (de) * 1994-08-08 1996-02-15 Behringwerke Ag Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems
DE4439756C2 (de) * 1994-11-09 2002-07-18 Dade Behring Marburg Gmbh Kalibrator zur Verwendung in Testverfahren zum Nachweis eines defekten Gerinnungsfaktors V
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US5780255A (en) * 1995-06-09 1998-07-14 Instrumentation Laboratory, S.P.A. Protein C pathway screening test
US20030143759A1 (en) 1995-10-20 2003-07-31 Bjorn Dahlback Assays for determining anticoagulant cofactor activity
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism

Also Published As

Publication number Publication date
JPH08506181A (ja) 1996-07-02
EP0690991B2 (en) 2004-01-14
WO1994017415A1 (en) 1994-08-04
AU690535B2 (en) 1998-04-30
BR9406223A (pt) 1996-01-09
US7169572B1 (en) 2007-01-30
DE69411898D1 (de) 1998-08-27
HU9502190D0 (en) 1995-09-28
HUT72191A (en) 1996-03-28
CA2154080C (en) 2006-03-21
DK0690991T4 (da) 2004-02-16
ATE168781T1 (de) 1998-08-15
FI953565A7 (fi) 1995-07-26
AU5982794A (en) 1994-08-15
DE69411898T3 (de) 2004-07-08
EP0690991B1 (en) 1998-07-22
CZ184995A3 (en) 1996-03-13
US20070212743A1 (en) 2007-09-13
DK0690991T3 (da) 1999-02-01
DE69411898T2 (de) 1998-12-17
CA2154080A1 (en) 1994-08-04
PL310050A1 (en) 1995-11-13
PL181102B1 (pl) 2001-05-31
NZ261190A (en) 1997-12-19
GR3027697T3 (en) 1998-11-30
FI953565L (fi) 1995-07-26
FI953565A0 (fi) 1995-07-26
ES2119165T5 (es) 2004-07-01
EP0690991A1 (en) 1996-01-10

Similar Documents

Publication Publication Date Title
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
MX9402339A (es) Formulacion de proteina.
MX9302160A (es) Composiciones farmaceuticas del interferon de leu cocito humano concordante.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ES2080837T3 (es) Tratamiento de estados y enfermedades.
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
ES2119411T5 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
Diniz et al. Effectiveness of blood irradiation by modified intravenous laser (ILIB) on the clinical parameters of fibromyalgia
RU2005131578A (ru) Аплидин для лечения множественной миеломы
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
ES2069030T3 (es) Metodo para tratar funcionamiento defectuoso del corazon.
DE3777886D1 (de) Arzneimittel zur bekaempfung maligner und chronischer erkrankungen.
Whipple Jr The cure of a patient with a very resistant streptococcus viridans endocarditis with massive penicillin therapy (average daily dose of eighty-six million units)
ES2061821T3 (es) Utilizacion terapeutica del derivado ester isopropilo de monosialgangliosido en patologias nerviosas con componente inflamatoria.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19960401

FG2A Definitive protection

Ref document number: 690991

Country of ref document: ES